Legend

Presentation Icons

CME

Non-CME

In Person

On Demand

Live Stream

Active Learning

Choose Rheum

Emerging Investigator Awardee

All times listed are Central Daylight Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.

Type here to filter the list

Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
Immunological Complications of Medical Therapy Poster
Location: Hall F1
CE: 0.00
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1088: Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1089: Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1090: Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Amelia Khoo, M.D., M.Eng (she/her/hers) – Yale University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1091: Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Location: Hall F1
Abstract Poster Presenter: Betul Ibis, MD (she/her/hers) – Mount Auburn Hospital/Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1092: Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Location: Hall F1
Abstract Poster Presenter: Binod Kc, MBBS – SUNY Upstate Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1093: Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Blake Baay, BS – UT Southwestern
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1094: Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1095: Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
Location: Hall F1
Abstract Poster Presenter: dellal azeddine, n/a (he/him/his) – GHI LE RAINCY MONTFERMEIL
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1096: Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.
Location: Hall F1
Abstract Poster Presenter: Elisabet Perea-Martínez, MD – Rheumatology section, Hospital General Universitario de Elda
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1097: Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1098: Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Location: Hall F1
Abstract Poster Presenter: Francisco Arias, MD – University of Texas Rio Grande Valley
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1099: Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Location: Hall F1
Abstract Poster Presenter: Grace Haeun Lee, BA – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1100: Associations Between Pre-existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Gregory Challener, MD – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1101: Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Heba Altarawneh, MD – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1102: Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Location: Hall F1
Abstract Poster Presenter: Julia Barasch, MD – Weill Cornell - New York Presbyterian
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1103: Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Kayla Chubbs, MD – Dalhousie University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1104: Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1105: Association Between Pre-existing Rheumatoid Arthritis and Immune-related Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1106: Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Location: Hall F1
Abstract Poster Presenter: KO JEN LEE, MD, PhD – National Taiwan University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1107: Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1108: Baseline Features, Immunosuppression, and Immune-related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1109: Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Location: Hall F1
Abstract Poster Presenter: Laurianne Simard, MD (she/her/hers) – Université Laval
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1110: Tumor outcomes and arthritis flares in patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitor therapy
Location: Hall F1
Abstract Poster Presenter: Madalyn Walsh, MD, BS – University of Iowa
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1111: Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study
Location: Hall F1
Abstract Poster Presenter: Maja Ivanovic, MD (she/her/hers) – University of Chicago Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1112: Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Location: Hall F1
Abstract Poster Presenter: Manush Sondhi, MD (he/him/his) – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1113: Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Location: Hall F1
Abstract Poster Presenter: Qi Wang, MD – Metrohealth System/Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1114: Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Location: Hall F1
Abstract Poster Presenter: Qiang Xu, n/a – Guangzhou University of Traditional Chinese Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1115: Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Location: Hall F1
Abstract Poster Presenter: Samuel Bitoun, MD, PhD – Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1116: Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Location: Hall F1
Abstract Poster Presenter: Sarah Sun, MD, PhD – Stanford University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1117: Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review
Location: Hall F1
Abstract Poster Presenter: Scott Yeudall, MD, PhD – The Johns Hopkins Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1118: Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
Location: Hall F1
Abstract Poster Presenter: Settawut Buadee, MD – Faculty of Medicine, Siriraj Hospital, Mahidol university, Thailand
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1119: Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Location: Hall F1
Abstract Poster Presenter: Shady Younis, PhD – Stanford University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1120: Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Location: Hall F1
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1122: A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-related Problems
Location: Hall F1
Abstract Poster Presenter: William Koch, PhD, DO – University Hospitals
Monday, Oct 27th
4:00 PM - 5:00 PM Central Time
27M72: Cancer Immunotherapy and Its Toxicities, Today and Tomorrow
Location: W375A
Moderator: Jeffrey Sparks, MD;MSc – Brigham and Women's Hospital
Moderator: Sophia C. Weinmann, MD, FACR – Duke University
Session Coordinator: Janet Pope, MD, FRCPC, MPH – University of Western Ontario
Session Coordinator: Brittany Adler, MD – Johns Hopkins University
CE: 1.00
Monday, Oct 27th
4:00 PM - 4:30 PM Central Time
Current Cancer Immunotherapy Landscape and the Future
Location: W375A
Speaker: Aliyah Pabani, MD, MPH – Johns Hopkins
Monday, Oct 27th
4:30 PM - 5:00 PM Central Time
When Cancer Therapy Triggers Autoimmunity: The Rheumatologist’s Role in Immune Checkpoint Inhibitors Toxicity
Location: W375A
Speaker: Elad Sharon, MD,MPH – Dana-Farber Cancer Institute
Tuesday, Oct 28th
8:30 AM - 9:30 AM Central Time
28T05: The Good, the Bad, and the Ugly: Understanding Mechanisms of Adverse Events After Immune Checkpoint Therapy
Location: W181A-C
Moderator: Sophia C. Weinmann, MD, FACR – Duke University
Session Coordinator: Teresa Tarrant, MD – Duke University
CE: 1.00
Tuesday, Oct 28th
8:30 AM - 8:50 AM Central Time
Pathogenesis of Immune checkpoint inhibitors-induced myocarditis
Location: W181A-C
Speaker: Daniela Cihakova, PhD – Johns Hopkins University
Tuesday, Oct 28th
8:50 AM - 9:10 AM Central Time
Molecular and Immune Hallmarks of Immune-Related Adverse Event Inflammatory Arthritis Induced by Checkpoint Inhibitors
Location: W181A-C
Speaker: Roza Nurieva, PhD – University of Texas MD Anderson
Tuesday, Oct 28th
9:10 AM - 9:30 AM Central Time
Mouse Model of Immune-Related Adverse Events
Location: W181A-C
Speaker: Abby Overacre, PhD – University of Pittsburgh
Tuesday, Oct 28th
10:00 AM - 11:30 AM Central Time
28T19: Abstracts: Immunological Complications of Medical Therapy
Location: S102
Abstract Moderator: Vibeke Strand, MD, FACP, MACR – Stanford University School of Medicine, Palo Alto CA
Abstract Moderator: Vanessa Smith, MD, PhD – Ghent University Hospital
CE: 0.00
Tuesday, Oct 28th
10:00 AM - 10:15 AM Central Time
1728: Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Location: S102
Presenting Author: Huaxia Yang, MD – Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tuesday, Oct 28th
10:15 AM - 10:30 AM Central Time
1729: The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
Location: S102
Presenting Author: Didzis Gailis, MD – LMU University Hospital
Tuesday, Oct 28th
10:30 AM - 10:45 AM Central Time
1730: Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
Location: S102
Presenting Author: Deanna Jannat-Khah, MPH, DrPH – Hospital For Special Surgery
Tuesday, Oct 28th
10:45 AM - 11:00 AM Central Time
1731: A Post-marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-cell Therapy Using the FDA Adverse Event Reporting System
Location: S102
Presenting Author: Malvika Gupta, MD (she/her/hers) – Mayo Clinic
Tuesday, Oct 28th
11:00 AM - 11:15 AM Central Time
1732: Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Location: S102
Presenting Author: Takemichi Matsui, MD – Icahn School of Medicine at Mount Sinai
Tuesday, Oct 28th
11:15 AM - 11:30 AM Central Time
1733: Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Location: S102
Presenting Author: Adela Francis-Malave, BS (she/her/hers) – University of Pennsylvania, Perelman School of Medicine